Wells Fargo upgraded GeneDx (WGS) to Overweight from Equal Weight with an unchanged price target of $155. The firm views the stock’s 50% decline since December as overdone. The current valuation is attractive and discounts WGeneDx’s “competitive moat and growth runway,” the analyst tells investors in a research note. Wells sees the company’s expanded sales force and new markets as share catalysts in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx upgraded to Overweight from Equal Weight at Wells Fargo
- Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today
- GeneDx Holdings: Robust Growth, Structural Tailwinds, and Undervalued Long-Term Potential Support Buy Rating
- Cathie Wood Doubles Down on High-Potential Biotech Plays
- Top 5 Trending Stocks by Unusual Trading Volume, 1/13/26